Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q2 2022 · 10-Q
Revenue$0.00$0.00no prior Q2 2021 on file Net Income-$67.41M-$67.41MN/M vs Q2 2021 EPS Diluted-$1.31-$1.31N/M vs Q2 2021 Operating Income-$65,827,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$62,060,000N/M ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end